What happens when the science does not fit the story we have been told

Some people start losing weight on GLP-1 drugs before they notice any change in appetite. That does not fit the standard story.

If these drugs worked purely by making you eat less, the order would be simple: you feel less hungry, you eat less, you lose weight. But doctors are noticing something different. Some patients drop weight in the first few weeks, before the hunger suppression kicks in. Something else seems to be happening.

This is not proven. It is doctors noticing a pattern, not a full study. And appetite is tricky. You might be eating less without realising it. You might feel just as hungry, but actually put less on your plate. The early weight loss could be water, not fat. Several things could be happening at once. We do not know for sure. But the question it raises is worth taking seriously.

For years, the weight loss field has operated under one dominating theory: calories in, calories out. The physics of energy balance is not being disputed. Burn more than you consume, and you will lose weight.

What GLP-1 drugs challenge is not the physics. It is the framing placed on patients: that weight is simply a matter of willpower, that failure to lose is down to personal weakness, and that biology plays only a minor role in what is mostly a behavioural problem (i.e. greed and laziness).

That framing has failed many people. They were eating well, moving regularly, and doing what they were told. Their biology was not cooperating. And no one could explain why.

New research offers a different lens. It has less to do with appetite. More to do with how your cells burn fuel.

The Debate That Never Went Away

The calorie model was never the only theory.

For decades, researchers have proposed alternatives. Some said the body defends a set weight and fights back when you try to change it. Others argued that the type of food matters more than the amount. Studies showed that metabolism slows when you diet, making it harder to keep weight off. None of these ideas disappeared. They just got drowned out.

The calorie model won because it was simple. It placed responsibility on the individual. It fit neatly into NHS Eat Well messaging. And for some people, it worked.

But for many, it did not. GLP-1 drugs are reopening old questions. Not because they prove any single alternative, but because they work in ways the simple “eat less, move more” advice cannot explain.

One Possible Piece: How Your Cells Use Energy

Your cells have two main ways to make energy. Cells can rely more heavily on sugar or shift toward burning stored fat. Burning sugar is quick, but you do not get much power from it. Tapping into and burning fat stores is slower but far more efficient.

In some people, cells get stuck using the fast, wasteful method. The tiny power plants inside cells, called mitochondria, do not work as they should. Sugar burns fast. Fat stays put. Weight loss becomes harder than it should be.

GLP-1 drugs seem to shift this balance. One theory behind this is that they help cells work better first, and the appetite suppression follows later. If true, it changes the story of how these drugs work.

A 2023 study gives some support to this idea. Researchers looked at 255 people with type 2 diabetes and 175 healthy people. Of those with diabetes, 59 were taking GLP-1 drugs, and 196 were not. Those on GLP-1 drugs showed signs that their cells were working more efficiently. Importantly, the two diabetes groups had similar blood sugar levels and body measurements, which suggests the cell-level changes were not just a beneficial side effect of better blood sugar control.

This is not considered proof, scientifically speaking. The study watched what happened rather than testing it directly. Patients were not randomly assigned to their prescribed treatments. The differences could reflect other things about the patients themselves. And no one has shown yet that these cell improvements lead directly to weight loss.

But the pattern fits a bigger idea: GLP-1 drugs fix something deeper, and the appetite effects come second.

What Else Could Explain It

The cell energy story is not the only possibility.

Other things could explain why some people lose weight before feeling less hungry. Your brain might respond to GLP-1 before you consciously notice any change in appetite. You might be eating less without realising it. The drug could change your behaviour before changing how you feel.

Early weight loss might also be water, not fat. When blood sugar drops, the body releases stored water. The number on the scales moves, but not because your metabolism has changed.

And the order might be backwards. Better insulin control, a known effect of GLP-1 drugs, could be what improves cell function, not the other way around.

None of these rules out the idea that these drugs work at a deeper level. But it complicates the picture. The honest answer is that we do not yet know which explanation is right, or whether several are true at once.

Beyond the Scales

GLP-1 receptors are not just in the gut. They appear in the heart, brain, and immune cells.

This is one reason researchers think these drugs do more than just reduce appetite. It does not prove anything on its own, but it opens up the question.

GLP-1 may not be mainly an appetite hormone. It may be a signal that helps coordinate how your body uses energy across many systems. If true, weight loss is just one part of the story.

Signs of Brain Benefits

GLP-1 receptors are found throughout the brain, including areas that control memory and thinking. This has led researchers to ask: could these drugs protect against diseases like Alzheimer’s?

Large studies have found striking patterns. A 2024 Swedish study followed 88,381 older adults with type 2 diabetes for about four years. After adjusting for other factors, results showed that those prescribed GLP-1 treatments had a 31% lower risk of developing dementia.

This kind of study cannot prove that the GLP-1 medication cut their dementia risk. People given newer, more expensive drugs may be more engaged in managing their health, developing habits that cut dementia risk on their own. Their healthcare team may also be more proactive in monitoring and reviewing their progress.

Clinical trials tell us more. In 2024, results from the ELAD trial were shared at a major conference. This was a proper trial where 204 patients were randomly assigned either a daily GLP-1 injection (liraglutide) or a placebo (dummy medication) for one year, with a 50:50 split. It was blind, meaning patients did not know which they were taking.

The results were mixed. The trial missed its main goal: there was no clear difference in how well the brain used sugar between groups. But among those who finished the full year, patients who had been injecting liraglutide showed slower decline on one thinking test. Brain scans showed less shrinkage in memory areas.

Why might GLP-1 drugs affect the brain? In Alzheimer’s, the brain struggles to use sugar for energy. Even when sugar is present, brain cells cannot access it properly. Some researchers call this “Type 3 diabetes,” though the term is debated.

GLP-1 drugs may help sugar cross from the blood into the brain more easily. They also seem to reduce brain swelling and slow the build-up of harmful proteins. But whether this leads to real benefits for people with Alzheimer’s is still unproven.

Larger trials are underway. Two studies with over 1,800 people with early Alzheimer’s are testing semaglutide. Results are expected in 2026. If those trials show thinking benefits alongside weight loss, the deeper theory gains support. If they show benefit without significant weight change, the case for direct brain effects becomes stronger. If they fail, this chapter closes.

What the Sceptics Say

The idea that these drugs work at a deeper level is appealing. It may also be too early to say.

Most of the cell-level research comes from lab and animal studies. The human evidence comes from watching what happens, not from testing it directly. Even well-designed studies cannot prove that the drug caused the changes, only that they happened together.

The dementia findings face the same problem. Even though results indicated large risk reductions, this can be challenging to prove when tested properly. The ELAD trial was the first real test. It was small, short, and missed its main goal.

None of this rules out the theory, but it is important to be cautious before making big claims about GLP-1 medicines.

What This Means for You

If you have struggled with weight despite truly managing your food and lifestyle, it may be worth talking to your GP about GLP-1 drugs.

These drugs are not free of side effects. Nausea and gut symptoms are common at first, though they usually ease after a few weeks. GLP-1 drugs work best with balanced eating and regular movement. They are not right for everyone, and some health issues mean they should not be used.

Growing evidence is testing the old story that weight is simply a matter of discipline. Hormones, cell energy, and metabolism all play a role. For years, patients were told to try harder when their biology was working against them.

For many people, these drugs offer the chance to work with their biology rather than against it.

The Bigger Picture

For decades, weight science acted as if the answer were settled: calorie deficit, willpower, behaviour. Whilst this was never wrong, the story built on top of it was always incomplete. The idea that weight is a personal failing, that biology bends easily to effort.

GLP-1 drugs are reopening that conversation. Not because they prove everything is about how cells use energy, but because they work in ways the old “just try harder” message cannot explain. Patients who “failed” diets are succeeding on these drugs. The simplest reading is that the drugs do what willpower could not. A deeper reading is that willpower was never the right frame.

That gap, between what we told people and what their bodies were actually doing, may be the most important thing GLP-1 drugs have shown us.

The research is still early, and the theory is unproven. The brain benefits are uncertain. But the questions these drugs have raised will outlast any single study.

If appetite was never your problem, how your body uses energy might be part of the answer. But more than that: the way we have always talked about weight may have been the problem all along.

If you have questions about whether GLP-1 drugs might suit you, please speak to your prescriber or pharmacist. They can help you weigh the benefits and risks for your case.

References

1. Luna-Marco C, et al. Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes. Redox Biology. 2023;66:102849.
2. Zheng Z, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduction and Targeted Therapy. 2024.
3. Edison P, et al. Liraglutide in mild to moderate Alzheimer’s disease: a phase 2b clinical trial. Nature Medicine. 2025.
4. Tang B, et al. Comparative effectiveness of glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden: an emulated trial study. EClinicalMedicine. 2024;73:102689.

This article is for general information. It doesn't replace advice from your own doctor, pharmacist or prescriber.